{"id":1260,"date":"2026-01-15T16:58:10","date_gmt":"2026-01-15T21:58:10","guid":{"rendered":"https:\/\/www.cpd.utoronto.ca\/cpeg-gcep\/?page_id=1260"},"modified":"2026-01-15T17:21:51","modified_gmt":"2026-01-15T22:21:51","slug":"session-learning-objectives","status":"publish","type":"page","link":"https:\/\/www.cpd.utoronto.ca\/cpeg-gcep\/agenda\/session-learning-objectives\/","title":{"rendered":"Session Learning Objectives"},"content":{"rendered":"

Symposium I – Bone & Mineral Metabolism Disorders<\/h3>\n

Achondroplasia and Hypochondroplasia Management including Evolving Therapies<\/strong>
\nAfter this presentation, you will be able to:<\/p>\n

    \n
  1. Describe clinical characteristics of achondroplasia and hypochondroplasia and how to differentiate between them<\/li>\n
  2. Review the role of Fibroblast Growth Factor Receptor 3 (FGFR3) gene as a “negative regulator” of bone growth<\/li>\n
  3. Assess benefits and limitations of novel growth-modulating therapies, specifically vosoritide (C-type natriuretic peptide analogue) in mitigating long-term complications and improving linear growth<\/li>\n<\/ol>\n

    Bone Mineral Metabolism Phosphate Wasting<\/strong>
    \nAfter this presentation, you will be able to:<\/p>\n

      \n
    1. Identify the molecular mechanisms of renal phosphate handling<\/li>\n
    2. Map the pathophysiology of FGF23-Mediated Disorders<\/li>\n
    3. Differentiate between genetic and acquired causes of hypophosphatemic rickets<\/li>\n<\/ol>\n

      ← Return to Agenda<\/a><\/p>\n

      \n

      Symposium II \u2013 Endocrine Late Effects of Cancer Therapy<\/h3>\n

      Endocrine Late Effects of Cancer-Related Therapy<\/strong>
      \nAfter this presentation, you will be able to:<\/p>\n

        \n
      1. Identify the spectrum and prevalence of endocrine late effects in childhood cancer survivors<\/li>\n
      2. Recognize treatment-specific risk factors and dose-response relationships for endocrine toxicity<\/li>\n
      3. Apply evidence-based surveillance strategies for early detection and management of endocrine complications<\/li>\n<\/ol>\n

        ← Return to Agenda<\/a><\/p>\n

        \n

        Oral Abstracts I and II<\/h3>\n

        After these presentations, you will be able to:<\/p>\n

          \n
        1. Describe recent research activity in the field of Pediatric Endocrinology and Diabetes within Canada<\/li>\n
        2. Apply key insights from recent research into their own education\/clinical\/research practices<\/li>\n<\/ol>\n

          ← Return to Agenda<\/a><\/p>\n

          \n

          Symposium III – Congenital Hyperinsulinism (CHI)<\/h3>\n

          Update on Genetics of Congenital Hyperinsulinism & Imaging and Surgical Outcomes in Congenital Hyperinsulinism<\/strong>
          \nAfter these presentations, you will be able to:<\/p>\n

            \n
          1. Evaluate current medical management options including diazoxide and somatostatin analogues<\/li>\n
          2. Differentiate between focal, diffuse, and atypical forms of CHI using [18F]-DOPA PET\/CT imaging to guide surgical planning<\/li>\n
          3. Examine emerging pharmacological therapies such as novel glucagon analogues and monoclonal antibodies targeting insulin receptors<\/li>\n<\/ol>\n

            ← Return to Agenda<\/a><\/p>\n

            \n

            Symposium IV \u2013 Diabetes<\/h3>\n

            Stem Cell Transplantation<\/strong>
            \nAfter this presentation, you will be able to:<\/p>\n

              \n
            1. Understand the evolution from cadaveric islet transplantation to stem cell-derived beta cell therapy<\/li>\n
            2. Recognize the key challenges limiting widespread clinical adoption and strategies to overcome them<\/li>\n
            3. Evaluate current clinical outcomes and future directions for cell replacement therapy in diabetes<\/li>\n<\/ol>\n

              Universal Screening\/Intervention in T1DM<\/strong>
              \nAfter this presentation, you will be able to:<\/p>\n

                \n
              1. Describe the natural history of islet autoantibodies in the progression of type 1 DM<\/li>\n
              2. Recognize the historical successes, present-day challenges, and future implications in standardizing lab assays to detect and quantify islet autoantibodies<\/li>\n
              3. Assess the benefits and limitations of measuring and monitoring islet autoantibodies in clinical decision-making<\/li>\n<\/ol>\n

                ← Return to Agenda<\/a><\/p>\n

                \n

                Debate<\/h3>\n

                Should Sensor-Augmented Insulin Pump therapy be started at diagnosis of type 1 diabetes mellitus (T1DM)?<\/strong>
                \nAfter this presentation, you will be able to:<\/p>\n

                  \n
                1. Understand current guidelines for use of technology in the management of T1DM at diagnosis<\/li>\n
                2. Review the advantages and disadvantages of pump therapy at diagnosis of T1DM<\/li>\n
                3. Consider different perspectives in caring for children with T1DM<\/li>\n<\/ol>\n

                  ← Return to Agenda<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

                  Symposium I – Bone & Mineral Metabolism Disorders Achondroplasia and Hypochondroplasia Management including Evolving Therapies After this presentation, you will be able to: Describe clinical characteristics of achondroplasia and hypochondroplasia and how to differentiate between them Review the role of Fibroblast Growth Factor Receptor 3 (FGFR3) gene as a “negative regulator” of bone growth Assess […]<\/p>\n","protected":false},"author":43,"featured_media":0,"parent":36,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-full.php","meta":{"footnotes":""},"class_list":["post-1260","page","type-page","status-publish","hentry"],"meta_box":{"cpde2_sidebar_image_std":"","cpde2_sidebar_image_custom":"","cpde2_sidebar_image_alt":"","cpde2_subnav":"200","cpde2_map_addresses":[],"cpde2_additional_page_sections":[],"cpde2_comment_city":""},"_links":{"self":[{"href":"https:\/\/www.cpd.utoronto.ca\/cpeg-gcep\/wp-json\/wp\/v2\/pages\/1260","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cpd.utoronto.ca\/cpeg-gcep\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.cpd.utoronto.ca\/cpeg-gcep\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.cpd.utoronto.ca\/cpeg-gcep\/wp-json\/wp\/v2\/users\/43"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cpd.utoronto.ca\/cpeg-gcep\/wp-json\/wp\/v2\/comments?post=1260"}],"version-history":[{"count":0,"href":"https:\/\/www.cpd.utoronto.ca\/cpeg-gcep\/wp-json\/wp\/v2\/pages\/1260\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.cpd.utoronto.ca\/cpeg-gcep\/wp-json\/wp\/v2\/pages\/36"}],"wp:attachment":[{"href":"https:\/\/www.cpd.utoronto.ca\/cpeg-gcep\/wp-json\/wp\/v2\/media?parent=1260"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}